Aranesp Sales Data

Rank 94 Current sales rank, all
U.S. Pharmaceuticals.

Last updated: February 2014 (updated quarterly).
The following data shows Aranesp U.S. retail sales in Q4 2013 compared to previous quarters.

Date Range Sales Rank Sales ($000) Units (000)
Q4 2013 94 (12) -9.22% -11.43%
Q3 2013 82 (2) 1.83% 1.66%
Q2 2013 80 -1.61% -2.43%
Q1 2013 80 (4) -3.03% -4.63%
Q4 2012 76 (5) -4.44% -4.78%
Q3 2012 71 (2) -1.51% -3.55%
Q2 2012 69 (3) -3.66% -3.75%
Q1 2012 72 (6) -5.86% -7.86%
Q4 2011 66 (15) -6.07% -3.64%
Q3 2011 51 (3) -10.25% -11.29%
Q2 2011 48 (3) -1.03% -1.33%
Q1 2011 51

* Units refer to the number of packages sold.

Source: IMS Health (Midas). Please review our terms of use and attribution guidelines. Copyright - All rights reserved. Unauthorized use and/or duplication of this material without express written permission is strictly prohibited.

Related News

DateArticle
November 25, 2013FDA Sends Amgen Letter Over Aranesp Direct Mailer
June 24, 2011FDA Modifies Dosing Recommendations for Erythropoiesis-Stimulating Agents
October 19, 2010FDA Advisers Back Anemia Drugs for Kidney Patients
October 19, 2010FDA Panel Backs Anemia Drugs For Kidney Disease
February 16, 2010FDA Tightens Controls on Anemia Drugs
December 3, 2008FDA Issues Questions and Answers on Medication Guides for Erythropoiesis-stimulating Agents (ESAs).
September 26, 2008Anemia Drugs Linked to Stroke Study Deaths: FDA
Hide
(web4)